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1.1 Biocatalysis  
Biocatalysis is the application of enzymes, cellular extract or whole cells in 
synthetic chemistry for the production of building blocks or high added-value 
chemicals 1. Although enzymes have been utilized in fermentation processes as a 
means to produce and preserve foodstuffs (such as cheese, bread and wine) 
before their discovery for thousands of years, the purposeful use of biocatalysts 
in chemical transformations processes only started in the late 19th century 1,2. In 
the first half of the 20th century researchers in academia and industry learned 
how to use whole cells, cell extracts or partially-purified enzymes in different 
biocatalytic processes 3. One of the first examples of enzymatic biocatalysis, 
described by Rosenthaler in 1913, is the asymmetric synthesis of R-
mandelonitrile by treating benzaldehyde with hydrogen cyanide in presence of a 
plant extract (containing an enzymatic mixture, which included oxynitrilase) 4. 
Despite the fact, for example that oxynitrilases have been employed (as crude 
extract) since the early 20th century for chemical synthesis, only recently they 
have become broadly used in industrial applications. In present days, enantio-
selective oxynitrilases are commercially available and they are used for the 
asymmetric production of various cyanohydrins, which are raw materials for the 
synthesis of different chiral compounds 5,6. An early obstacle in the exploitation 
of enzymes in catalysis was the production of a sufficient amount of the 
biocatalyst. 
Traditionally, enzymes were isolated from their native sources: fungi, insects, 
plants, or mammals. However, this process was often time-consuming and, in 
many cases, extraction yields were very limited 2,3. This situation has radically 
changed thanks to advancements in the field of biotechnology. The development 
of the technology of recombinant DNA allowed the overexpression of the 
enzymes of interest in host organisms from different native species such as E. 
coli or B. subtilis 7. In this way, large quantities of enzymes became accessible at 
a relatively low cost 3 and enzyme-based biocatalysis became an economically 
and sustainable alternative to chemical synthesis on an industrial scale 1.  
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The first wave of biocatalysis (1900s to1980s, Fig. 1) was based on the use of 
natural enzymes, such as the use of proteases in laundry detergents 8, the use of 
glucose isomerase for the conversion of glucose to D-fructose 9 and the use of 
penicillin G acylase to produce semisynthetic antibiotics 10. The main challenge 
in these bioprocesses was the limited stability of the biocatalysts. The 
development of the immobilization techniques of enzymes improved their 
operational stability and facilitated also their recovery and recycling, enabling a 
significantly reduction of the costs of biocatalysis 1,11.  
In the second wave of biocatalysis (1980s to 1990s, Fig. 1) companies such as 
Novozymes and Genencor were established with the aim to produce on large 
scale and commercialize bulk enzymes for the food, textile, detergent and 
chemical industry 12. During this period, protein engineering based on structural 
information enabled the alteration of the enzyme’ s substrate specificity, allowing 
the synthesis of unnatural intermediates 1. Therefore, the use of the enzymes have 
been integrated in several industrial biotransformation reactions, in particular for 
the production of compounds used for the synthesis of pharmaceuticals, 
agrochemicals and fine chemicals 13,14. By the 1990s many enzymes were 
commercially available 3 and in 2015, the global market of industrial enzyme was 
estimated to be worth $ 8.18 billion/year. Projections suggest that the market will 
reach $ 17.50 billion by 2024 15. An early example of an enzymatic process, 
developed and industrialized by DMS-Andeno, was the synthesis of a key chiral 
precursor for the production of diltiazem (a blood pressure drug). This process 
involves the asymmetric hydrolysis of a chiral glycidate ester by lipolase (a 
lipase from T. lanuginous), a commercial enzyme used in various industrial 
applications 16. More recently, Pfizer used the same lipase in a chemoenzymatic 
treatment to produce the active compound of the anticonvulsant drugs Lyrica® 
with high yields 17. Other examples are the use of hydroxy nitrile lyase for the 
synthesis of herbicides 18 or the use of nitrile hydratase for the production of 
acrylamide 19.  
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In the mid 1990’s Pim Stemmer and Frances Arnold introduced the concept of 
the directed evolution of enzymes. This technology consists of iterative cycles of 
random mutagenesis, followed by screening of mutant libraries to identify 
variants with improved properties such as increased stability, altered substrate 
specificity or strict enantioselectivity 20. Recently, the directed evolution 
approach and the rational design approach (supported by bioinformatic analysis) 
were integrated to improve the chance of success by creating “smaller but 
smarter” libraries 
1
. The latest frontier of protein engineering is the “de novo 
design” of enzymes with new functions. This approach requires the exhaustive 
knowledge of the structure-function and dynamics-function relationships 21,22. 
The wide application of enzymes as biocatalysts can be attributed to the several 
environmental and economic benefits of their exploitation. They possess several 
advantageous features such as a high chemo-, regio- and enantioselectivity and a 
high catalytic efficiency under mild conditions. Enzymes which act only on a 
single enantiomer of the substrate can be employed as biocatalysts in processes 
such as the deracemization or the dynamic kinetic resolution of racemic mixtures 
23. Their high selectivity prevent the accumulation of by-products during the 
bioconversion 2,24. Moreover, it is relatively simple to set-up efficient catalytic 
enzymatic cascades, since most enzymatic reactions are performed under similar 
conditions. Biocatalysts can be used in transformations reactions without the 
need of blocking and deblocking steps or activation of functional groups required 
in canonical enantio- or region-selective organic chemistry reactions making 
enzymes an environmentally friendly alternative to conventional inorganic 
catalysts. The success of industrial biocatalysis eventually depends, on the cost-
effectiveness of the whole process. Since, despite the progress of industrial 
biocatalysis, in many cases, the traditional chemical process remains 
economically competitive. The main challenge of the modern industrial 
biotechnology is the developing a broad range of cheap, robust and versatile 






Figure 1. Time-line of the evolution of biocatalysis (Figure modified from 25). 
1.2 The development of the biocatalytic process 
To fully establish biocatalysts in industrial applications, it is necessary to tailor 
enzyme properties so that they are optimal not only under laboratory conditions, 
but also in the context of the industrial process in which the catalyst will be 
applied 26. The process optimization belongs to the field of biocatalysis 
engineering and consists in the development of enzymatic-based systems as a 
whole using different strategies (e.g., medium and protein engineering, 
biocatalyst formulation, down-stream processing) and it will play an important 
role in the next future 2. 
The biocatalysis engineering, thanks to new technologies and to an increased 
understanding of basic biochemistry and bioinformatics, allowed the 
development of new and less expensive biocatalyst applications increasing the 
impact of enzyme technology in industry. Several key aspects have to be 
considered during the design and improvement of a biocatalytic process. The 
main ones are the optimization of the reaction conditions and of the in vitro 
evolution and production of the enzymes. Finally, biocatalysis engineering and 
downstream-processing enhancements facilitate product recovery and recycle of 
the biocatalyst; this two aspects drastically reduce the biotransformation costs 
2,27. The different steps in the development of a biocatalytic process and some of 
their major issues are shown in figure 2. As a general rule, the several aspects of 
the industrial process must be take into account using a rational approach. The 
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biocatalytic processes are improved in an iterative manner taking into account 
also the costs of the processes themselves 24. The starting point of the biocatalysis 
design is the identification of a target reaction or of an industrial process product 
that could be optimized by enzymes technology. The next step is the selection of 
a suitable biocatalyst that can be commercially available or can be identified 
from the natural biodiversity (by screening of organisms or enzymes able to 
catalyze the desired biotransformation). The “natural” biocatalyst can be 
improved in order to acquire the desired properties and to match the desired 
applicative conditions. This can be obtained by metabolic pathway or protein 
engineering. A critical, and often under rated issue, is the identification of an 
effective formulation of the biocatalyst. For example, immobilization of the 
biocatalyst generally improves its shelf life under process conditions and 
facilitates its recovery and reuse 24,27. Finally, since downstream processing 
represents a significant part of the cost of the whole bioprocess (up to 50% in 
several cases), an efficient and cost-effective recovery and purification procedure 
of the reaction product must be developed 27,28. 
 
Figure 2. The biocatalysis cycle. Key steps and selected challenges in the development 
of a biocatalytic process (Figure modified from 24). 
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1.3 Selection of the biocatalysts  
Biocatalysis can be classified based on the biocatalyst exploited in the process, 
that is a whole cell or an isolated enzyme biocatalyst 29. During the design and 
development of several biocatalytic processes, a critical point is the choice 
between an isolated enzyme or a whole-cell biocatalyst 30.  
Processes developed before the 1960s were mainly based on whole-cell 
biocatalysis since the techniques for an efficient and cost-effective purification of 
the proteins were not yet available. However, through the 1960s and 1970s, 
several methods for effective and affordable purification of enzymes were 
developed allowing use of isolated enzymes as biocatalyst on a large scale. The 
subsequent introduction of recombinant DNA technology in the 1980s permitted 
to enhance protein expression which, together with the development of enzyme 
immobilization techniques, allowed the reuse of the catalyst resulting in an 
overall reduction of the enzyme costs 31.  
The choice of the type of biocatalyst defines the architecture of the process. As a 
general rule, processes based on isolated enzymes require investments upstream 
of the reactor (i.e. the main cost is the preparation of the biocatalyst), while 
whole-cell processes require investments downstream (i.e. the main cost is the 
recovery and purification of the reaction products) 31. In this respect, the 
economic sustainability of the whole process should be considered in order to 
select between the whole cell and the isolated enzyme biocatalysts. 
1.3.1 Whole cell biocatalysts 
In the whole cell catalysis approach, the cell growth phase, during which the 
enzyme of interest is produced, and the production phase, during which the 
resting cells convert the substrates into the desired products, are separated 32. 
Accordingly, typical biotransformation processes consist into two stages: in the 
first one, cells are grown, and in the second one they are harvested and 
resuspended in the medium for the biocatalytic process. This step allows to 
remove unconsumed growth substrates as well as undesired metabolites that were 
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produced during cell growth, enabling a simpler and more efficient recovery of 
the products, this simplifying the downstream processing 33.  
To produce effective whole cell biocatalysts, single or multiple enzymes must be 
expressed into host cells according to the complexity of the synthetic pathway 
required to produce the desired product(s). Indeed, to maximize the performances 
of whole cell biocatalysts, metabolic engineering and synthetic biology strategies 
can be used to optimize pathway flows and to enhance the productions of the 
target compound 34. E. coli is the most promising microbial host to generate 
heterologous synthetic pathways (synthetic biology) on large-scale and at low-
cost 34. As a matter of fact, in recent years E. coli (or even yeast strains) have 
been engineered for the production of isobutanol 35, opiods 36 and antimalarial 
drug artemisinin 37.  
Whole cell biocatalysts (derived from natural organisms or genetically modified 
expression hosts) represent the cheapest biocatalyst formulation since there is no 
need for the lysis of the cells and for the purification of the enzymes 34. 
Moreover, the cellular endogenous metabolic pathways allow an efficient 
cofactor regeneration avoiding the addition of expensive external cofactors (e.g. 
NADH or NADPH), which are needed for complex biotransformation reactions, 
making the processes economically convenient 38,39. In the whole cell system the 
recycling of cofactors can be achieved providing a suitable co-substrate and 
exploiting in vivo a secondary enzyme activity 31,39,40. Several whole cell 
biocatalyst applications based on single step or multistep bioconversions to 
produce fine chemicals are reported in literature 34,39. For example, the group lead 
by Dominguez de Maria used lyophilized E. coli whole-cell expressing carbonyl 
reductase from C. parapsilosis to produce S-phenylethanol starting from 
acetophenone and using n-propanol as a co-substrate for the cofactor 
regeneration. Under optimal conditions, the researchers reached a product titer of 






Figure 3. Biocatalytic reduction of acetophenone using E. coli cells with overexpressed 
carbonyl reductase (CPCR) (Figure modified from 41). 
 
Another relevant advantage of whole cell systems is the coexpression of multiple 
enzymes which allows to set up an efficient reaction cascade (due to the presence 
of different catalysts in a confined space) 39. However, coexpression of multiple 
enzymes can results a high metabolic burden during cell growth, which may lead 
to an insufficient overexpression and thus unsuitable catalytic performance 42. In 
addition, another disadvantage of whole cell biocatalysts can be the limitation in 
mass transfer 39. The cell usually uptakes nutrients and natural substrates 
exploiting specific membrane transport mechanisms. However, bioconversions 
applied in industrial synthetic chemistry in general use non-natural compounds as 
substrates, whose mechanisms of uptake may not exist. Consequently, the 
reactants are transported into the cell by diffusion, a process that often becomes 
the rate-limiting step 31. Classical methods to overcome this problem are the 
permeabilization of the cell wall by treatment with chemical agents (surfactants, 
chelating agents, or organic solvent) or the coexpression of specific membrane 
transporter (selective permeabilization) 39.  
It must be highlighted that because of the high complexity of cell metabolism, the 
optimization of metabolic pathways for improving the product yield is often 




1.3.2 In vitro enzymatic biosynthesis 
To address some of the major manufacturing problems of whole-cell biocatalysts 
and to address the high technical challenges of in vivo synthetic biology, purified 
(or partially purified) enzymes represent an alternative strategy for the set up of 
bioconversion reactions12,43. In cell-free systems, one or more enzymes and 
coenzymes can be used together in vitro to catalyze a specific enzymatic cascade 
for the production of desired compounds 44. When using pure enzymes, the 
absence of the physical barrier formed by cell membranes allows the free and 
easy access of reactants to the catalysts, enables the maintenance of the optimal 
reaction conditions and facilitates the monitoring of the progress of the reaction 
43,45. In comparison to whole-cell biocatalyst, cell-free biocatalysts show also 
high product yield, fast reaction rate, high product titer and volumetric 
productivity, easy product separation and considerable high product quality 
(because of the absence of side reactions) 12. Despite the advantages outlined 
above, application of free enzymes in industry requires to overcome several key 
challenges, which have been recently addressed by applied research:  
1) the cost-effective production of the biocatalyst can be achieved by reducing 
the cost of the purification procedures. In this respect, it is even possible to use 
cell-free (crude) extracts to catalyze the desired reactions. In this case, no 
purification steps are required but, in the case of whole cell biocatalysis, 
metabolic engineering could be desirable to prevent undesired enzymatic side-
reactions. Another approach to reduce the purification cost is the use of 
thermophilic enzymes (or better, stable enzymes), which can be purified by a 
simple heat treatment which eliminate the mesophylic enzymes by precipitation 
43. Thermophilic enzymes have been employed to produce a variety of products 
such as pyruvate 46, myo-inositol 47 and glutathione 48; 
2) the enhancement of the enzyme stability by immobilization techniques, which 
also facilitate the recovery of the biocatalyst; 




The main field of application of in vitro enzymatic biosynthesis is the fine 
chemical or pharmaceutical industry, where the additional efforts and costs for 
the preparation of the biocatalyst (mainly due to protein purification and/or 
immobilization) are compensated by a more strict and fine system control of the 
whole process (including reproducibility, control of the yield and increased 
optical purity) 49. One of the most successful examples of the application of 
purified enzymes in the pharmaceutical industry is the development of a 
biocatalytic process for producing building-block used in the synthesis of drugs 
(such as in the case of atorvastatin or montelukast). These compounds were 
synthetized starting from a regio- and stereospecific hydroxylation of the first 
precursor catalyzed by a keto-reductase (KRED, from L. kefir) in combination 
with other enzyme(s) 50 (Fig. 4).  
 
Figure 4. Regioselective reduction of a key intermediate in synthesis of montelukast by 
KRED (Figure modified from 50). 
 
 
Another interesting example is the enzymatic production of 7-
aminocephalosporanic acid (7-ACA), which is used for the synthesis of semi-
synthetic cephalosporins. The standard bioconversion is represented by two-step: 
starting from cephalosporin C, the D-amino acid oxidase (DAAO, EC. 1.4.3.3) 
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catalyze the oxidative deamination of the amino-adipyl group to give the 
corresponding α-ketoadypyl-7ACA, which spontaneous decarboxylate to produce 
glutaryl 7-ACA; this latter compound is hydrolyzed by glutaryl-7-
aminocephalosporanic acylase (Gl-7-ACA, EC 3.5.1.93) to produced the final 
product (Fig. 5) 51–53. 
Other applications of enzymes in cosmetic, textile and paper industry are 






Figure 5. Two-step bioconversion of cephC to 7-ACA by D-amino acid oxidase and 






Table 1. Whole cell and isolated enzymes biocatalyst: main advantage and disadvantages 
56. 
 
Whole cell Isolated enzymes 
Advantages Disadvantages Advantages Disadvantages 
Better reaction control Cofactor 
regeneration system 
necessary 
Simple and cheap Unwanted side 
reaction 

























Easy protein engineering    
1.4 Protein engineering 
Present enzymes evolved over millions of years to operate most effectively on a 
narrow range of natural substrates under physiological conditions. In contrast, 
industrial biocatalysis, requires the biotransformation of synthetic substrates 
under harsh condition (e.g. elevated temperature or in the presence of organic 
solvents) 29,57. Consequently, wild-type enzymes exploited as biocatalysts in 
synthetic organic chemistry and biotechnology, suffer from several limitations 
when used to transform unnatural substrates: poor catalytic efficiency, 
insufficient regioselectivity or stereoselectivity, narrow substrate scope and 
insufficient stability under operating conditions 3. Hence, wild-type enzymes are 
often not suitable for biocatalytic processes. To increase the industrial 
productivity (space-time yields) and selectivity enzymes need to be re-designed 
29,57. The optimization of industrial enzymes is achieved by protein engineering 
2,20 (Fig. 6). 
The choice of the protein engineering approach for the improvement of the 
enzyme, a process also named in vitro evolution, depends upon the following 
criteria 58: 
1) the availability of structural information: namely, the availability of the 
high-resolution three-dimensional structure of the protein of interest or of a 
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reliable structural model built exploiting the sequence similarity with 
proteins of whose the 3D structure has been solved (homology modeling); 
2) the availability of functional information: a deep knowledge in the structure-
function relationships will facilitate/direct the selection of the mutagenesis 
approach;  
3) the capacity of the screening step of the library variants: the size of variant 
libraries obtained after the mutagenesis step must be in the range of the 
capacity of the screening/selection method available. For example, in vivo 
selection assays allow the analysis of very large libraries (up to 1012 
variants). Unfortunately, this method can be employed only to optimize the 
features of enzymes directly related to cell survival/growth 59. Other high-
throughput screening methods, such as the fluorescent activated cell sorting 
(FACS), allow the screening of up to 105-107 variants 60. On the other hand, 
if a spectrophotometric assay is the sole technique available, only small 
libraries up to 200 clones can be screened 58; 
4)  the property of the enzymes that need to be optimized: changes in activity, 
selectivity or substrate specificity often involve mutations of residues close 
to the active site, while improvements in stability require modification of 
residues that in several cases are for away from the active site 61.  
Two main different strategies are commonly employed to in vitro evolve a 
biocatalyst (Fig. 6): the rational design and the directed evolution approach. In 
addition, these two approaches can be combined in a semi-rational design 
approach (see below). Recently, thanks to the advances in computational 
methodology and of the improved knowledge of the physical principles that 
underlie protein folding, the de novo protein design approach is developing with 
an increasing pace. This approach aims to create new proteins that are not based 
on existing sequences (i.e. proteins design from scratch) 62. However, despite the 
availability of  highly sophisticated computational algorithms and of a growing 
number of 3D protein structures used as training set, the success rate of the de 
novo design is still low and limited 63. As a proof of the concept, a successful 
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example is Top7, a 93-residue alpha/beta globular protein designed with a novel 
fold not observed in nature, described in Kuhlman et al., 2003 64. However, 
several main bottlenecks of de novo design have not yet been completely solved: 
the full understanding of the structure-function relationships, the protein folding 
mechanism, the detailed knowledge of protein dynamics and of the 
conformational changes induced by the interaction with the ligand. In addition a 
huge computational capacity is required to analyze a large data volumes 





Figure 6. Overview of protein engineering strategies by ration design, directed evolution 
and combined methods 65.  
1.4.1 Rational design 
Rational design by site-directed mutagenesis (SDM), introduced by Smith and 
coworkers in the late 1970s 66, involves the introduction of site-specific 
mutations that allow the replacing a particular amino acids with one of the other 
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19 canonical ones into the coding sequence of the protein of interest. In order to 
improve the enzymatic properties (such as, substrate specificity, activity) of the 
protein of interest by SDM, a detailed knowledge of the relationships between 
structure and function in the target enzyme must be available 2,20. This 
information can be achieved from analysis of the 3D structure(s) of the protein of 
interest by in silico studies (such as molecular dynamic, docking analysis). For 
example, amino acids that hinder substrate access to the active site or release of 
product can be identified by the analysis of the 3D structure and subsequently 
substituted with the aim to improve the enzyme performance 67,68. 
The availability of an increasing number of protein experimental structures (or 
reliable 3D models), of bioinformatic methods and of biochemical data, spurs the 
use of rational design approaches. One of the advantages of this approach is the 
possibility to introduce potentially beneficial mutations in an enzyme without the 
need to generate variant libraries (shotgun); this is a desirable condition when no 
high-throughput assay system is available 65. However, it is difficult to predict all 
potential effects of mutations. Therefore, it is not surprising that often inserted 
substitutions do not produce the expected effect 65,69. 
1.4.2 Directed evolution 
Directed evolution is an effective method of protein engineering, which 
reproduces the natural Darwinian evolution in a test tube 3. The major advantage 
of directed evolution is that no structural information is required. Traditionally, 
directed evolution involves an iterative protocol to create genetic diversity by 
random mutagenesis or in vitro recombination, followed by the screening (or 
selection) variant libraries (Tab. 2), in order to identify improved enzyme 
variants showing the desired phenotype 3,70.  
Several strategies for creating genetic variability have been developed based on 
random mutagenesis such as error prone PCR (ep-PCR) 71, DNA shuffling 72 and 
several homology-independent in vitro recombination approaches (i.e. Staggered 
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Extension Process, StEP 73 or, Incremental Truncation for the Creation of Hybrid 
enzyme, ITCHY 74). 
An example of directed evolution is based on  ep-PCR is the generation of 
variants of the protease subtilisin E possessing improved stability in presence of 
organic solvents such as dimethylformamide (DMF) 75. Although, early 
applications of directed evolution were focused to increase the enzymes stability 
under specific reaction conditions, more recently this approach has been 
exploited to improve other important enzyme properties. In 1997, as a proof of 
concept, Reetz and coworkers enhanced the enantioselectivity of the lipase from 
P. aeruginosa used as biocatalyst in the hydrolytic kinetic resolution of the chiral 
ester rac-16 76. The main issue in the application of directed evolution is the 
generation of large libraries of variants; this requires the development of a robust, 
fast and cheap high-throughput screening (or, possibly, a in vivo selection 
method) to identify the desired interesting 65. Indeed, its success is based on the 
integration of an efficient library construction with a reliable and high-throughput 
screening assay 77. It is necessary to underline that, although using suitable 
experimental approaches libraries composed by millions of variants can be 
analyzed, only a tiny fraction of the vast possible sequence space for an average-
size protein can be sampled 70. To reduce this sequence space (increasing the 













Table 2. Exploited selection and screening methods used in directed evolution 78.  
Strategy Library size Advantage Disadvantage Examples 
1. Selection ~109 Yields desirable 
variant only 
































Difficult to detect 




2. Screening methods    
Agar plate screening ~105 Simple to operate Limited dynamic 
range  
Conversion of a β-






















~109 Large libraries Fluorescent 









Cell as microreactor ~109 Large libraries Fluorescent 
detection only 
 
Cell surface display ~109 Large libraries Fluorescent 
detection only 
Displaying antibody 
libraries on the 
surface of E. coli 
and binding with 
fluorescent label 
antigens resulted in 
antibodies with high 
affinities 
mRNA display ~1012 In vitro selection 
and evolution of 
proteins. 
Search of de novo 





Extensively used to 
isolate binding 




1.4.3 Semi-rational design 
Semi-rational design combines the directed evolution with the rational design 
approach; this approach results into the generation of small (but smart) libraries 
of variants 70,79. Typically, in the “semi-rational” design approach, the knowledge 
derived from the analysis of protein sequences, biochemical or structural data and 
predictive computational algorithms is used identify amino acid positions in the 
protein, which are preselected as promising targets for mutagenesis 70,80. The 
most efficient strategy to introduce genetic diversity is the site-saturation 
mutagenesis (SSM) 81,82, a technique in which all the 20 naturally amino acids is 
randomly introduced in one or more specific position of the protein. This is 
obtained by using a mutagenesis primer containing one or more degenerated 
codons(NNN) or a reduced subset of them based on the degeneracy of the genetic 
code (e.g., NNK and NDT where N: adenine/cytosine/guanine/thymine; K: 
guanine/thymine and D: adenine/guanine/timine) 82–84. Next, interesting variants 
can be identified by functional library screening. Semi-rational design allows the 
generation of small, high-quality libraries and avoid the need for high-throughput 
screening methods for library analysis 70,80. 
A popular semi-rational strategy used to improve substrate scope and/or 
enantioselectivity is the Combinatorial Active Site Saturation Test (CASTing), 
which uses the information derived from structural data to select amino acid 
residues in the active site pocket. These residues are then exhaustively mutated 
by site-saturation mutagenesis one by one and in combination in order to observe 
potential synergistic effects that can be missed when only one residue at time is 
mutated. The first example of this approach, is reported in Reetz et al., 2001 85: 
the stereoselectivity of Pseudomonas aeruginosa lipase (PAL) was enhanced by 
SSM at four residues using mutagenic oligonucleotides containing the NNK 
degenerated codon by subjecting to screening only 5000 variants. A variant of 
CAST strategy that can be employed to enhance the thermostability or resistance 
to chemical denaturation of enzymes is the B-Factor Iterative test (B-FIT) 82,86. In 
this case site-saturation mutagenesis is focused on highest flexibility sites, which 
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are identified from the analysis of the distribution of the B-factor from X-ray 
data. Another variant of the CAST approach is the Iterative Saturation 
Mutaghenesis test (ISM) in which SSM is applied in a systematic manner 82,87. 
ISM is a rational extension of the original CAST approach, which can be applied 
to improve several catalytic parameters 88. In this strategy, the chosen sites of 
randomization (e.g., A, B, C, in Fig. 7) are independently subjected to SSM, 
creating the first generation of libraries. Subsequently, a variant from each library 
is used as a template for a second step of mutagenesis at the remaining three sites 
(e.g., B, C, D), and the process is continued until all sites have been mutated once 
in a given upward pathway (Fig. 7). 
 
Figure 7. Scheme of iterative site-saturation mutagenesis at four sites (A, B, C and D). 
The vertical axis symbolizing an improved property 88.  
 
Another strategy to identify “hotspot” of functionality in the protein sequence is 
the use of evolutionary information. Multi sequence alignments (MSAs) and 
phylogenetic analysis (e.g., using the web-platform Consurf 89) have become 
standard means to evaluate amino acid conservation and ancestral relationships 
between sequences and structure of homologous proteins 70,80. This approach 
allows to identify residues of the target protein that are poorly conserved during 
evolution. These positions represent evolvable residues that can be substituted 
without altering the stability of the protein. Consensus design, the one used in 
like ancestral protein reconstruction approach, has been used to improve the 
thermostability of several proteins 65. For example, Bommarius and his group, 
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combining this approach with structural data, were able to increase the thermal 
stability of a glucose dehydrogenase and penicillin G acylase from B. subtilis. In 
both cases, due to the core full selection of the mutagenesis sites, about 50% of 
the variants showed improved thermostability 90,91. Another example was the use 
of this approach by Conti et al., 2014 with the aim to alter the enzyme substrate 
scope of cephalosporin C acylase. The best variant is H57βS-H70βS-L154βY 
glutaryl acilase VAC variant, which shows the highest production of 7-amino 
cephalosporanic acid (3.5 fold higher than wild-type) 92. 
1.5 Formulation of the biocatalyst: enzyme 
immobilization 
After the identification of an enzyme suitable for the desired biotransformation, 
the optimization of its properties (such as substrate scope, stability, 
enantioselectivity) by protein engineering and its production in large amounts at 
relatively low cost, the following step is the set up of an effective biocatalyst 
formulation. Since enzymes are soluble in water their recovery from the reaction 
mixture is challenging. Consequently, many enzymes can be only employed as 
single-use biocatalyst 20,29. The enzyme cost per kg of product can be drastically 
reduced through the development of an easily recoverable and reusable 
heterogeneous biocatalyst. This kind of biocatalyst can be obtained by protein 
immobilization 11. The immobilized biocatalyst results in simplification of the 
biocatalysis process, in the improvement of the product quality and in the 
achievement of a cost effective process. Importantly, enzyme immobilization can 
enhance the stability of the protein toward chemical or thermal denaturation 
2,20,29. 
Basically, the methods for enzyme immobilization can be categorized into three 
classes: binding to an inert support (carrier), entrapment (encapsulation) or cross-






Figure 8. Different techniques for enzyme immobilization 11. 
1.6 Stereoselective biocatalysis 
The increasing demand of optically pure chiral compounds in the pharmaceutical 
industry is due to the restrictions applied by international regulation agencies. 
Unsurprisingly, almost 60% of the 400 new active substance entities approved 
world-wide between 2002 and 2011 are formed by enantiopure compounds while 
racemates represent only 11% of the total amount 93. The enantioselective 
synthesis of chiral compounds is a challenge in organic chemistry. The creation 
of a specific chiral center in organic synthesis is not obvious, although 
approaches based on organometallic and organocatalytic methods, which used 
complex catalysts to induce asymmetry in selected transformations have been 
developed. The intrinsic chirality of enzymes and they ability to catalyze a wide 
range of chemical reactions, make them powerful tools for the development of 
stereoselective biotransformation 94. The use of enzymes for enantioselective 
biocatalysis turned out to be a competitive approach both in terms of yield and 
cost in comparison to the classical asymmetric synthesis due to the possibility of 
developing highly stereoselective biotransformations in a sustainable manner 23. 
The synthesis of single enantiomers of pharmaceutical and drug building blocks 
is of special interest, not only because of side effects caused by the opposite drug 




1.6.1 Kinetic resolution 
The biocatalytic kinetic resolution (KR) has enjoyed a considerable growth in the 
past few decades and is become a favorite industrial production method nowday 
for the synthesis of bioactive natural product and derivates. In the KR of racemic 
mixtures, stereoselective biocatalysts react with only one of the two enantiomer 
of a racemic solution allowing to obtain an optically pure product and leaving an 
unreacted optically pure substrate behind. Hence, KR represents a useful 
preparative method in research and industrial applications, despite its maximal 
yield is 50%. Esterases, proteases and lipases are often applied in kinetic 
resolution owing to their ease of production and application at industrial scale. 
Also, a large number of hydrolases have been used to resolve racemic mixtures 
of esters, amides, lactones, epoxides, hydantoins and nitriles (exploiting the 
hydrolytic reaction) as well as, for kinetic resolutions of amines and alcohols 
(exploiting the reverse reaction) 96. For instance, P. cepacia lipase 
commercialized by Amano (Amano PS) has been successfully used to catalyze 
the resolution of aristelegone B a bioactive natural tepenoid-derivated. Using 5 
molar equivalent of vinyl acetate as a acyl donor and acetone as a solvent, after 
36 h at 25 °C the (+)-acylaristelegone B (46% yield and 96% ee ) and (–)-
aristelegone B (54% yield and 94%) were obtained 97. The same enzyme has 
been applied in the first step of the production of the (+)-artabotriol, a the 
precursor for the synthesis of several bioactive product such as (-)-tulipalin B 






Figure 9. KR of racemic dimethylenesuccinate for the of (+)-artabotriol by P. cepacia 
lipase 94. 
1.6.2 Deracemization 
Dynamic kinetic resolution (DKR) and stereoinversion reaction are the two most 
common strategies to obtain the racemic mixtures deracemization (Fig. 10). DKR 
is, in principle, a KR process in which the non-catalyzed enantiomer is racemized 
in situ. During an enantioselective process the biocatalyst promotes the 
transformation of one enantiomer into the product, while the other enantiomer is 
racemized (at a comparable rate), restoring the racemic mixture 99. The 
racemization step can be performing by enzymes (e.g., racemase) or non-enzyme 
catalysts (e.g., transition metal) 23. 
While the maximal yield of KR is 50% of the product, in DKR a 100% 
conversion can be reached following the optimization of  the two reactions 96,99.  
Biocatalytic stereoinversion is a process in which one enantiomer of the racemic 
substrate is enantioselectively transformed into an intermediate (typically, non-
chiral) that is, in turn, transformed (by non-enantioselective catalyst or by an 
enantioselective catalyst with the opposite stereo-preference catalyst) giving the 
starting racemic compound and accumulating the opposite enantiomer. The 
reiteration of the non-enantioselective reaction allows the complete 





Figure 10. DKR and stereoinversion strategies (Figure modified from 99). 
 
Deracemization by stereoinversion can be used, for example, for the 
interconversion of chirals alcohols through the corresponding ketones, as well as 
for the interconversion of amines/amino acids through the corresponding 
ammines. This can be achieved through the combination of an enantioselective 
oxidative step with a non-selective reducing agent 23,99. In figure 11 is reported 
the stereoinversion reaction to obtain the production of optically pure L-2-
naftilalanine (L-2-Nal) from the corresponding racemate by an enzymatic system 
formed by three different enzyme working in the same reaction condition. The 










Desymmetrization reactions are used for the production of optically pure 
compounds starting from non-chiral reagents such as meso- or prochiral 
compounds. As in the case of the deracemization process, the desired enantiomer 
can be obtained with a theoretical yield of 100%. The main advantage of this 
approach is the production of high amounts of enantiopure compounds by a 
simple reaction. This is in contrast to KR or stereoinversion reactions, where 
iteration or combination of different steps are required 96. For instance, [(1R,6S)-
6 (hydroxymethyl)cyclohex-3-en-1-yl]methyl acetate is used as building block 
for the production of (–)-alloyohimbane and (–)-yohimbane, antihypertensive and 
antipsychotic drugs. The enantioselective synthesis of this compound is obtained 
by the hydrolysis from the meso-diacetate precursor catalyzed by the porcine 
pancreas lipase (PPL, EC 3.1.1.3). The desired monoacetate intermediate is 





Figure 12. Chemo-enzymatic synthesis of (–)-alloyohimbane and (–)-yohimbane 




1.7 Industrial applications of D-AAs and α-keto 
acids 
D-AA and α-keto acids are high value added compounds for the fine chemistry, 
since they are used for the synthesis of pharmaceutical drugs, food additives and 
insecticides 102,103.  
1.7.1 D-amino acids 
D-AAs are commonly used for the synthesis of semi-synthetic antibiotics (such 
as semi-synthetic penicillins and cephalosporins) or therapeutic peptides. Drugs 
containing D-amino acids assimilated and processed more slowly than other 
drugs in humans. For example, aspoxicillin which contains D-Asp has a more 
extended half-life and a lower tendency to bind serum proteins to amoxicillin 104 
while the substitution of D-His and D-Cys in the Pro-His-Ser-Cys-Asn peptide 
(ATN-161) determines a potent inhibition of invasion and lung colonization 
effects in human prostate cancer 105. In addition, D-AAs can enhance the activity 
of antimicrobials against biofilms 106. In the food industry, D-AAs are used for 
the synthesis of food additives such as of the sweetener alitame (L-Asp-D-Ala 
dipeptide), which has 10-fold higher sweetening potency than aspartame and it is 
used in the diets of diabetic patients. Furthermore, D-AAs themselves can be 
used as food additives and flavor agents. Finally, D-AAs can be added in 
cosmetic preparations 102.; it has been reported that D-Asp has antioxidant effects 
and D-Ser reduced ultraviolet damage. 
1.7.2 α-Keto acids  
α-Keto acids are used in various applications such as in pharmaceutical, in fine 
chemical, in food and animal feed industries. As replacement of the protein 
amino acids, the α-keto acids such as α-ketoisovalerate and α-ketoisocaproate can 
be used as nitrogen-free substitutes for essential amino acids in patients with liver 
and kidney diseases to avoid the accumulation of nitrogen-containing metabolites 
103,107. Also, they are used to treat patients with chronic glomerulonephritis and 
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hepatitis B virus infection 108. Another important application of α-keto acids is 
their use as building blocks in organic chemistry, owing to the presence of the 
carbonyl group. For example, they are precursors of the biofuel n-butanol 35, or 
can be used for the production of L- and D-amino acids 109.  
The main α-keto acids and their application are summarized in Table 3. 
 
Table 3. Summary of the major α-keto acids and their applications 103. 
Keto acids Application 
 




Procursor of pharmaceutical chemicals 
 
α-ketoglutaric acid Ammonium ion receptor 
Precursor of chemical compounds 
Improve athletic performance  
The poly α-KG used in tissue scaffolding and therapeutic delivery 
 
α-ketoisovalerate acid Precursor of 1-butanol 
Hepatitis B virus infection and chronic glomerulonephritis 
Feed of lamb, pig, chickens  
 
α-ketoisocaproate acid Precursor of biofuel 
Hepatitis B virus infection and chronic glomerulonephritis 
Depression of silenced tumor with organoselenium compounds 
Stimulate insulin secretion 
Increase muscular power 
Promote the milk production and composition  
 




Poultry industry, anti-cancer drug 
 
2,5-diketo-D-gluconic acid Precursor of 2-keto-L-gulonic acid  
 
2-ketobutyric acid Precursor for chemical synthesis of pesticide, spice and food additive 
 
Oxaloacetic acid A key metabolite in tricarboxylic acid cycle 
 
2-oxoadipic acid A key metabolite of tryptophan and lysine  
 




Metabolic intermediate in L-lysine synthesis 






1.8 Synthesis of optically pure D-amino acids (D-
AAs) and α-keto acids  
D-amino acids (D-AAs) and α-keto acids can be produced by chemical synthesis, 
fermentation or enzymatic biotransformation. Bio-based catalysis can provide D-
AAs and α-keto acids with high a degree of purity and with a high productivity 
by green processes 102,103.  
1.8.1 D-AAs enzymatic production 
The enzymatic production of D-AAs has been performed exploiting hydrolases, 
oxidoreductases, and aminotransferases. Some examples are shown below: 
1. D-Hydantoinase ( EC. 3.5.2.2) and D-carbamoylase (EC. 3.5.1.77) 
D-Hydantoinase coupled with D-carbamoylase is an efficient system for 
producing D-AAs in industry. Several natural D-AAs, including D-Trp, D-Phe, 
D-Val, D-Ala, and D-Met are produced by this method 110. In addition, also 
several unnatural amino acids are produced in huge amounts (several thousand 
tons of product per year). In particular, the most significant are D-phenylglycine 
and D-p-hydroxyphenylglycine, which are used as building block for the 
synthesis of semisynthetic penicillin and cephalosporins. 
This enzymatic biocatalytic process utilizes D,L-5-substituted hydantoins as 
starting substrate and is formed by two steps: D,L-5-substituted hydantoins are 
first hydrolyzed into their carbamoyl derivatives by the strictly enantioselective 
D-hydantoinase and then into corresponding D-AAs by a decarbamoylation 
catalyzed by the D-carbamoylase 102 (Fig. 13A). 
2. D-Stereospecific amidohydrolase 
D-Stereospecific amidohydrolases, such as N-acyl-D-amino acid 
amidohydrolase, D-amino acid amidase and D-peptidase, can be used for 
dynamic kinetic resolution of racemic amino acid amides to produce D-amino 
acids, starting from mixture of amides of D,L-amino acid derivatives producing 
the corresponding D-AA and fatty acid. The D-amidohydrolases reacts with the 
D-enantiomer of the N-acyl-D,L amino acid. The in situ racemization can be 
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performed by an L-amino acid amide racemase (or by a chemical reaction 
starting from the unreacted N-acyl-L-anino acid. The racemic amides could be 
hydrolyzed to D-amino acid with a theoretical yield of 100 %. D-AAs produced 
using this approach include D-Arg, D-Leu, D-Ala and D-Leu 111 (Fig. 13B). 
3. D-Amino acid aminotransferase (EC 2.6.1.21) 
D-Amino acid aminotransferase catalyzes the transfer of the amino group from 
D-amino acids to α-keto acid to yield the corresponding D-amino acids. For 
example, the D-AAT from L. salivarius can be exploited as biocatalyst, to 
aminate several α-keto acids (e.g., α-ketobutyrate, glyoxylate and indole-3-
pyruvate) to produce their corresponding D-amino acids 112 (Fig 13C).  
4. D-Amino acid dehydrogenase (EC 1.4.99.1) 
D-AADHs are NADPH-dependent oxidoreductases, which can catalyze the 
stereoselective reductive amination of α-keto acids into their corresponding D-
amino acids. However, D-AADHs are only marginally applied for the industrial 
D-amino acid production because they are rare in Nature and they are usually 
membrane-bound proteins 102 (Fig. 12D).  
5. L-Amino acid oxidases/deaminase (EC 1.4.3.2) 
L-Amino acid oxidase/deaminases (LAAO/LAAD) catalyze the oxidative 
deamination of L-amino acids with a strict enantioselectivity, providing a simple 
method to produce pure D-AAs from a racemic solution by dynamic kinetic 
resolution 107,113 (Fig. 13E). It is important to highlight that the D- substrates are 
more expensive than the corresponding L-form (e.g., D-Phe costs 4-fold more 
than L-Phe). LAAO from Rhodococcus opacus shows a broad substrate 
specificity, therefore this enzyme is used to produce a wide variety of D-AAs 





Figure 13. Examples of production of D-AAs by enzymatic synthesis. A) Enzymatic 
route for the production of D-p-hydroxyphenylglycin ; B) Commercial process for the 
production of D-AAs by N-acyl-D-amino acid amidohydrolase; C) D-Ala production by 
D-amino acid aminotransferase; D) Enzymatic system for the synthesis of D-
cyclohexyalanine by D-amino acid dehydrogenase BC621 variant; E) Production of D-




1.8.2 Enzymatic production of α-keto acids 
Several enzymes such as dehydrogenases, aminotransferases, DAAOs and 
LAAOs or LAADs can also be used for α-keto acids production from α-amino 
acids. However, it is important to highlight that the reactions catalyzed by 
aminotransferases or dehydrogenases require two substrates or an extra cofactor 
respectively, while DAAOs require expensive substrates (the D-enantiomers). 
Interestingly, the oxidation of L-amino acids by LAAO or LAAD requires only a 
single L-amino acid as a substrate (which is less expensive than the 
corresponding D-form) and do not require without extra cofactors; this makes 
LAAOs and LAADs the ideal enzymes for α-keto acids synthesis 103. For 
instance, LAAO from Rhodococcus sp. is used for the bioconversion of L-DOPA 
into the corresponding α-keto acid in presence of catalase to avoid the 
decarboxylation of the product 115. Similarly, LAAO from P. alcalifaciens and T. 
viride have been to convert N- -carboxy(CBZ)-L-Lys to its α-keto acid 116. 
1.9 Amino acid oxidases 
Amino acid oxidases (AAOs,) are enzymes that oxidize amino acids releasing 
ammonium and hydrogen peroxide. Based on the chirality of the amino acid used 
as substrate, these enzymes can be divided into two groups. D-amino acid 
oxidases (EC 1.4.3.3) are flavoenzymes showing strict specificity for D-amino 
acids 117. L-Amino acid oxidases (EC 1.4.3.2) are flavoproteins, with the 
exception of lysine oxidase from M. mediterranea which use cysteine 
tryptophylquinone as a cofactor 118, that oxidize L-amino acids releasing the 
corresponding α-keto acids in addition to ammonium and hydrogen peroxide.  
In particular, in this thesis I focus my attention on the flavoenzymes active on L-
AAs to generate compounds with which have potential application in medicine as 
antitumorals, antimicrobials 52,113.  
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1.10 L-Amino acid oxidase (LAAO) 
L-Amino acid oxidases, described by Zeller and Maritz (1944) 119 are 
flavoenzymes, which belong to the class of oxidoreductases. LAAO catalyzes the 
oxidative deamination of L-amino acids with a strict stereospecificity to give the 
corresponding α-keto acids with the production of ammonia and hydrogen 
peroxide via an imino acid intermediate (Fig. 14).  
 
 
Figure 14. Catalytic cycle of a generic L-amino acid oxidase (Figure modified from 113). 
The ability of LAAO to discriminate between L- or D-forms of the substrate lies 
in the architecture of their substrate binding pocket that conforms to the catalytic 
model proposed by Mesecar and Koshland 120. According to this model, the 
enantioselectivity of LAAO is based on the presence of three different binding 
interactions between the substrate and the active site and the particular 
orientation of the α-hydrogen of the substrate towards the N5 of the isoalloxazine 
ring of the cofactor. The main anchorage points are represented by a salt bridge 
interaction between the α-carboxylate of the amino acid (negatively charged) and 
the guanidinium group of an arginine of the active site (positively charged) that is 
located near the isoalloxazine ring. The second and third interaction are 
respectively represented by a hydrogen bond between the α-amino group of the 
substrate and the main protein chain belonging to a small residue (for example, 
glycine or alanine) and the hydrophobic region of the active site to which the 
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lateral chain of the substrate is located, a structural determinant responsible for 
the different substrate specificity in various LAAO 113 (Fig. 15).  
 
 
Figure 15. Binding modes and interactions between the α-amino and α-carboxylate group 
of the substrate and the active site residues of a “generic” LAAO (R = side chain of the 
substrate) (Figure modified from 113). 
LAAO activity is broadly distributed in nature, across diverse phyla from 
bacteria to mammals; (the major source of eukaryotic LAAO is the enzyme from 
venous snakes) 121. In different organism LAAOs differ both in cellular 
localization (intracellular, extracellular or membrane bound) and in biological 
function (which is related to the oxidation of L-amino acids and to the production 
of reactive oxygen species 122). Since LAAOs are able to produce hydrogen 
peroxide during catalysis, they play a main role in antimicrobial or 
cytotoxic/apoptotic processes such as the competition related to biocontrol 
between microbial species 123. Moreover, LAAOs isolated from prokaryotic 
organisms are involved in the production of ammonia and α-keto acids starting 
from free L-amino acids, which are used as a source of nitrogen and carbon for 
the growth of the microorganism itself 124. 
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From a biochemical point of view, LAAOs from different sources distinguished 
for molecular mass, substrate specificity and post-translational modifications. 
This diversity suggests that LAAOs underwent enormous evolutionary changes 
by divergent evolution from a putative ancestral protein 124. Most LAAOs show 
broad substrate specificity with a preference for hydrophobic substrates (e.g., L-
Phe, L-Leu, L-Trp), but there are several members that exhibit a very strict 
preference for a specific L-amino acid, such as L-aspartate oxidase or L-
phenylalanine oxidase 113. 
All LAAOs whose 3D structures were solved are present in solution as 
homodimers, with a molecular mass between 50 and 300 kDa. LAAO monomers 
fold in two domains: an FAD-binding domain and a substrate-binding domain 
which also hosts the amino acid residues that form the entrance funnel of the 
active site 113. In particular, the access to the active site of LAAOs is allowed by 
the presence of two different channels: a large channel connecting the re-face of 
the FAD to the solvent which is used by the substrate L-amino acid and the 
release of the product α-keto acid, and a small channel that connects the si-face 
of FAD to the solvent which is used by the molecular oxygen 125. The 
superimposition of the 3D structures of the LAAO present in the PDB database 
reveals a high conservation of the overall tertiary structure (RMSD of 2.0 - 2.2 
Å), despite of the low amino acid sequence identity (e.g., RoLAAO and 
CrLAAO share less than 23% of sequence identity). This indicates that these 
enzymes have been probably evolved through divergent evolution from a 
common ancestral protein giving rise to a family of evolutionarily-related LAAO 
enzymes 113. 
All LAAOs are subjected to post-translational modifications. Eukaryotic LAAOs 
need a high level of glycosylation for a correct maturation, secretion, and 
function. On the other hand, prokaryotic LAAOs are synthesized as inactive pro-
enzymes, which require a proteolytic cleavage to become active. The proteolytic 
activation, which is performed by an endopeptidase, occurs after the secretion of 
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the protein and represents a strategy to prevent cellular apoptosis due to H2O2 
production and depletion of intracellular L-amino acids 113,121. 
From the applicative point of view, LAAOs have important potential 
biotechnological applications: they are component of biosensors for a rapid and 
precise determination of L-amino acid concentrations in several biological, 
medical and food production applications. For example, a potentiometric 
biosensor based on LAAO 126 has been used in the food industry to control the 
nutritional quality of different products by their L-amino acids content. Although 
there are some drawbacks of LAAO biosensors (for example, their different 
sensitivity of detection for different amino acids) their applicability at industrial 
scale is much simpler and cost-effective in comparison to other analytical 
methods (e.g., HPLC-chromatography or spectrophotometric analysis) 127. 
In addition, snake venom LAAOs are known to induce antibacterial effects and 
apoptosis mediated by the hydrogen peroxide produced during the catalysis. 
These enzymes can be useful as antitumor and as therapeutic drugs against 
bacteria and leishmaniasis infections 121,128. For example, LAAO (ACTX-6) from 
D. acutus demonstrates cytotoxicity in vitro and inhibits HeLa cervical tumor in 
vivo by inducing apoptosis in a concentration and time-depending manner. For 
this reason, ACTX-6 is a potential anti-cancer drug.  
As previously reported, LAAOs can be used as catalysts in biotransformation 
113,127. However, the use of these enzymes on large-scale is rather limited. The 
production of recombinant enzymes (in particular for industrial biocatalysis) is 
essential to ensure the availability of large quantities of the biocatalyst at a low 
cost and to improve its biochemical properties through protein engineering. 
Currently, no LAAO with a wide substrate specificity has been successfully 
expressed in a recombinant form in prokaryotic hosts. The main bottleneck is 
represented by the cytotoxicity caused by the intracellular production of 
hydrogen peroxide from the overexpressed enzyme 113. LAAO from 




1.11 L-amino acid deaminase  
A suitable alternative is represented by L-amino acid deamminases (LAADs, EC 
1.4.99.B3). LAADs are membrane flavoenzymes that catalyze the stereospecific 
oxidative deamination of L-amino acids to the corresponding α-keto acid and 
ammonia. In this case, the electrons of the reduced cofactor (FADH2) are 
transferred to the membrane electron transport chain by a specific electron 
acceptor (probably a cytochrome b-like protein) without producing hydrogen 
peroxide.129.  
Unlike L-amino acid oxidase, several LAADs have been expressed as a 
recombinant protein in E. coli and have been biochemically characterized: type-I 
LAADs from P. mirabilis (PmirLAAD) 130 and from P. myxofaciens 
(PmaLAAD) 109 and type-II LAADs from P. vulgaris (PvLAAD) and from P. 
mirabilis (Pm1LAAD) 131. The 3D structure of PvLAAD 132 and PmaLAAD have 
been recently solved 129,132. 
In literature are reported several examples of LAAD applications as whole-cell 
133,134 or enzymatic biocatalyst135. Accordingly, there is an increasing in both 
scientific and practical interest to these enzymes. 
 
The review “Breaking the mirror: L-amino acid deaminase, a novel 
stereoselective biocatalyst” will give an overview of the structural and 
biochemical properties of LAADs and will summarized the advances that have 
been made in biocatalytic processes based on these enzymes. 
 
 
 
 
 
 
 
 
